Update on lymphocyte-activation gene 3 (LAG-3) in cancers: from biological properties to clinical applications  

作　　者：Lishu Zhao Hao Wang Kandi Xu Xinyue Liu Yayi He 

机构地区：[1]Department of Medical Oncology,Shanghai Pulmonary Hospital,School of Medicine,Tongji University,Shanghai 200433,China [2]School of Medicine,Tongji University,Shanghai 200092,China

出　　处：《Chinese Medical Journal》2022年第10期1203-1212,共10页中华医学杂志（英文版）

基　　金：This study was supported in part by National Natural Science Foundation of China(No. 81802255);Young Talents in Shanghai(No. 2019 QNBJ);"Dream Tutor" Outstanding Young Talents Program(No. fkyq1901);Clinical Research Project of Shanghai Pulmonary Hospital(No. fk18005);Key Discipline in 2019 (oncology), Project of Shanghai Municipal Science and Technology Commission (Project of Municipal Science and Technology Commission), and Scientific Research Project of Shanghai Pulmonary Hospital(No. fkcx1903)。

摘　　要：Immunotherapy that targets checkpoints, especially programmed cell death protein 1 and programmed cell death ligand 1, has revolutionized cancer therapy regimens. The overall response rate to mono-immunotherapy, however, is limited, emphasizing the need to potentiate the efficacy of these regimens. The functions of immune cells are modulated by multiple stimulatory and inhibitory molecules, including lymphocyte activation gene 3 (LAG-3). LAG-3 is co-expressed together with other inhibitory checkpoints and plays key roles in immune suppression. Increasing evidence, particularly in the last 5 years, has shown the potential of LAG-3 blockade in anti-tumor immunity. This review provides an update on the biological properties and clinical applications of LAG-3 in cancers.

关 键 词：Lymphocyte-activation gene 3(LAG-3) Immune checkpoint Cancer IMMUNOTHERAPY 

分 类 号：R730.51[医药卫生—肿瘤]